GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Alfresa Holdings Corp (TSE:2784) » Definitions » Debt-to-EBITDA

Alfresa Holdings (TSE:2784) Debt-to-EBITDA : 0.55 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Alfresa Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Alfresa Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円0 Mil. Alfresa Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円30,000 Mil. Alfresa Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was 円54,340 Mil. Alfresa Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.55.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Alfresa Holdings's Debt-to-EBITDA or its related term are showing as below:

TSE:2784' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07   Med: 0.11   Max: 0.64
Current: 0.64

During the past 13 years, the highest Debt-to-EBITDA Ratio of Alfresa Holdings was 0.64. The lowest was 0.07. And the median was 0.11.

TSE:2784's Debt-to-EBITDA is ranked better than
70.67% of 75 companies
in the Medical Distribution industry
Industry Median: 1.87 vs TSE:2784: 0.64

Alfresa Holdings Debt-to-EBITDA Historical Data

The historical data trend for Alfresa Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alfresa Holdings Debt-to-EBITDA Chart

Alfresa Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.10 0.13 0.08 0.07

Alfresa Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.06 0.10 0.27 0.55

Competitive Comparison of Alfresa Holdings's Debt-to-EBITDA

For the Medical Distribution subindustry, Alfresa Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alfresa Holdings's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Alfresa Holdings's Debt-to-EBITDA falls into.



Alfresa Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Alfresa Holdings's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1394 + 2461) / 51957
=0.07

Alfresa Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 30000) / 54340
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Alfresa Holdings  (TSE:2784) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Alfresa Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Alfresa Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Alfresa Holdings (TSE:2784) Business Description

Traded in Other Exchanges
N/A
Address
1-1-3 Otemachi, Chiyoda-ku, Tokyo, JPN, 100-0004
Alfresa Holdings Corp is a holding company engaged in the distribution of drugs. The company is in the Ethical Pharmaceuticals Wholesaling Business, the Self-Medication Products Wholesaling Business, the Manufacturing Business, and the Medical-Related Business. It mainly provides distributes diagnostic reagents and medical devices/equipment, health foods, supplements and other products to drug stores and pharmacies. The firm manufactures and markets high-quality active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices.

Alfresa Holdings (TSE:2784) Headlines

No Headlines